The Modulari-T Team

The people who built the first generation. Now building what comes next.

Modulari-T’s leadership team and advisory board have direct experience developing, manufacturing, and commercializing the first-generation autologous and in vivo CAR-Ts that created blockbuster brands and defined the fields.

Founding Team

Built by a tight-knit team with one mission.

Open link
Team Photo Tanya Borsuk V3

Tanya E.
Borsuk, PhD

CEO

Open link
Team Photo David Cotnoir White V2

David
Cotnoir-White, PhD

Co-founder,
President & CSO

Open link
Team Photo Stephanie Mok V2

Stephanie
Mok, PhD

Co-founder & COO

Open link
Team Photo Delphine Guipouy V2

Delphine
Guipouy, PhD

Co-founder,
VP of R&D

Why This Team

This isn’t a team that licensed existing technology.
They built the science it’s based on.

Most cell therapy companies start with an existing construct and optimize around it. Modulari-T’s founding team authored the research that revealed why the existing construct was fundamentally limited.

The MARC receptor and MoVe are both proprietary technology that originated from a decade of primary research into how the immune system’s own receptor architecture actually works.

In addition to the Founders, Modulari-T is supported by World Class Advisors that helped launch the first generations of ex- and in vivo CAR-T

Scroll to Top
Founding Team

Founding Team

Tanya E. Borsuk, PhD

Chief Executive Officer
Open link

Dr. Tanya E. Borsuk is the Chief Executive Officer of Modulari-T Biosciences. With close to 20 years of experience in Buy and Sell-Side Business Development, VC/Equity Investments, Platform and Pipeline Innovation, Business Insights, and Corporate Strategy across the Global Biotech and Pharmaceutical communities, Dr. Borsuk has worked to drive effective company start-ups and drug discovery across numerous technology platforms and therapeutic areas. She has participated in the launch of 9 FDA approved drugs, has helped close over $9B in Business Development transactions, and helped companies raise over $500M US.

She has been President and CEO of North49 LLC Consulting, a boutique consulting firm focused on Business Development and Strategy for Early- through Late-Stage Biotechs, and notable previous roles include fCBO at InduPro Therapeutics, CBO of Sitryx Therapeutics, Head of BD at Tegmine Therapeutics, Vice President of Pipeline Strategy and Alliances at Flagship Pioneering, and Co-Founder and Director of the Search and Evaluation of the Oncology & Cell Therapy Business Development teams at Celgene Corporation and Bristol Myers Squibb. She has also held several BOD positions and advisories.

Tanya holds a Doctorate in Cell Biology and Molecular Genetics from Rutgers University in New Jersey, a bachelor’s degree in Biology from Queen’s University at Kingston, Ontario, Canada, and a Mini-MBA from the Rutgers University Business School.

Founding Team

Founding Team

David Cotnoir-White, PhD
Co-founder, President & CEO
Open link

Dr. David Cotnoir-White is President, CSO and co-founder of Modulari-T.

Since the company’s founding, David has directed the development of Modulari-T’s MARC and MoVe technology platforms and the advancement of multiple programs across immunology, oncology and regenerative medicine. He has also played a key role in the early stages of company creation including early fundraising and team building.

David holds a PhD in Molecular biology, an MSc in structural biology and a BSc in Biochemistry from the Université de Montréal and McGill University. He has developed an expertise that bridges protein structure and engineering, pharmacology and therapeutic development in oncology and neurology.

In prior roles, he developed novel tools for drug discovery and worked on small molecules programs targeting solid tumor and neurodegenerative disease in collaboration with Merck at the Institute for Research in Immunology and Cancer, and with the CDRD (now adMare BioInnovation). David is also a Venture Partner at Pioneer Fund where he supports the investment teams of the Future of Health Fund.

Founding Team

Founding Team

Stephanie Mok, PhD

Co-founder & COO

Open link

Dr. Stephanie Mok is Chief Operating Officer and co-founder of Modulari-T. As COO, she leads the company’s core operations, including team recruiting, research lab buildout, and procurement. In addition, she leads the translation and process development for Modulari-T’s scientific work, supports business development, and contributes to fundraising, helping secure over $1M in non-dilutive capital to date.

Stephanie has a PhD in Chemical Engineering from McGill University, a MSc in Pathology, and a Bachelor of Medical Science in Pathology and Toxicology from the University of Western Ontario. She is also a Venture Partner at Pioneer Fund, a generalist pre-seed and seed stage investment fund and an early backer of Modulari-T, and a Y Combinator alumni.

Founding Team

Founding Team

Delphine Guipouy, PhD

Co-founder, VP of R&D

Open link

Dr. Delphine Guipouy is Vice President of Research & Development at Modulari-T, where she leads the development and validation of next-generation immunotherapies and advances programs toward clinical translation. She brings deep expertise in T- and NK-cell therapies, developed through academic innovation and biotech execution across Europe and North America.

Before joining Modulari-T, Delphine contributed to translational cell therapy programs in biotech, including roles at TxCell (now part of Sangamo Therapeutics) and Feldan Therapeutics, helping advance approaches from early research toward therapeutic application.

Delphine earned her PhD in Immunology from the University of Toulouse III, where her research focused on cytotoxic T-cell function spanning disease biology and therapeutic development, including the clinical-stage Ovasave program (TxCell). She completed postdoctoral training in Canada at University of Montreal, advancing NK cell-based therapies for solid tumors using approaches including CAR engineering and CRISPR (Feldan Therapeutics). Delphine holds an MSc in Immunology and Infectious Diseases and a BSc in Biology.